Obes Rev:体重与乳腺癌风险

2017-11-23 zhangfan MedSci原创

研究认为,总体上体重增加可降低女性乳腺癌风险,但对于30岁以下女性人群,过早的体重增加导致其绝经后乳腺癌风险增加。这些发现进一步证明了在一生中保持稳定体重的必要性

肥胖与成年乳腺癌风险的相关性,在绝经期前后正好相反--在绝经前高体重可降低乳腺癌风险;而绝经后,肥胖会导致乳腺癌风险增加,但之前的研究很少涉及30岁以下人群。

近日研究人员对PubMed和Web of Science数据库收集的资料进行检索,考察女性人群体重指数每增加5 kg m-2对乳腺癌风险的影响。

研究发现,总体而言,BMI每增加5 kg m-2,可降低对女性整个生命周期(14%)、绝经前(12%)以及绝经后(12%)的乳腺癌风险,研究结果存在较大的异质性和偏倚性,但偏倚性纠正后,结果保持不变。对于30岁以下女性人群的亚组分析显示了不同的结果,BMI每增加5 kg m-2,整体和绝经后乳腺癌风险增加13%和14%。

研究认为,总体上体重增加可降低女性乳腺癌风险,但对于30岁以下女性人群,过早的体重增加导致其绝经后乳腺癌风险增加。这些发现进一步证明了在一生中保持稳定体重的必要性。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2061691, encodeId=5d2f2061691f7, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Jan 30 19:22:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770289, encodeId=e4821e70289b4, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Tue Jun 19 06:22:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264065, encodeId=c67c26406562, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Nov 25 01:31:48 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263636, encodeId=25572636364d, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Thu Nov 23 14:42:26 CST 2017, time=2017-11-23, status=1, ipAttribution=)]
    2018-01-30 sjq027
  2. [GetPortalCommentsPageByObjectIdResponse(id=2061691, encodeId=5d2f2061691f7, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Jan 30 19:22:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770289, encodeId=e4821e70289b4, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Tue Jun 19 06:22:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264065, encodeId=c67c26406562, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Nov 25 01:31:48 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263636, encodeId=25572636364d, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Thu Nov 23 14:42:26 CST 2017, time=2017-11-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2061691, encodeId=5d2f2061691f7, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Jan 30 19:22:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770289, encodeId=e4821e70289b4, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Tue Jun 19 06:22:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264065, encodeId=c67c26406562, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Nov 25 01:31:48 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263636, encodeId=25572636364d, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Thu Nov 23 14:42:26 CST 2017, time=2017-11-23, status=1, ipAttribution=)]
    2017-11-25 sunfeifeiyang

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2061691, encodeId=5d2f2061691f7, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Jan 30 19:22:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770289, encodeId=e4821e70289b4, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Tue Jun 19 06:22:00 CST 2018, time=2018-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264065, encodeId=c67c26406562, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Nov 25 01:31:48 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263636, encodeId=25572636364d, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Thu Nov 23 14:42:26 CST 2017, time=2017-11-23, status=1, ipAttribution=)]
    2017-11-23 戒馋,懒,贪

    谢谢分享学习了

    0

相关资讯

Semin Oncol:解充血药可以“高效”饥饿癌细胞

国家癌症研究所的研究人员们一直在研究可以提到有害化疗药物的无毒替代物,近期,研究人员们发现一种感冒药的效果非常好,名为n -乙酰半胱氨酸(NAC)的药物是一种膳食补充剂,作为解充血药给孩子驱寒散瘀。

马力教授:如何认识、判断和应对乳腺癌HER2耐药

由中国医药教育学会乳腺疾病专业委员会河北分会及河北省医学会外科分会乳腺学组主办、河北医科大学第四医院乳腺中心承办的2017年乳腺癌新进展继续医学教育学习班暨乳腺癌多学科病例讨论会于11月17-18日在河北石家庄召开。河北医科大学第四医院马力教授应《肿瘤瞭望》邀请解答了如何认识、判断和应对乳腺癌HER2耐药。

Dev Cell:这种几乎无药可治的乳腺癌,竟然有了新靶点?

在乳腺癌里,有一种分类叫做“三阴性乳腺癌”。它并不常见,大概只占乳腺癌总数的10%。但它造成的死亡病例,却占到了乳腺癌患者死亡数的四分之一!

凌瑞教授:泛西北乳腺癌-高地论坛,努力提高西北地区乳腺癌规范化诊治水平

2017年11月18日,古城西安迎来了第五届泛西北乳腺癌-高地论坛的成功举办。本次“高地论坛”受到西北地区乳腺癌同道的高度关注,现场学术讨论气氛热烈。会后《肿瘤瞭望》有幸采访了大会主席、空军军医大学西京医院凌瑞教授。凌教授盘点了“高地论坛”的会议亮点,对提高西北地区乳腺癌规范化诊疗水平提出了展望。

Lancet Oncol:来曲唑治疗方案对早期乳腺癌患者无进展生存期的影响

研究认为对于绝经后激素受体阳性乳腺癌患者,来曲唑间歇治疗方案不能延长患者无进展生存期,接下来研究人员将考察来曲唑治疗方案延长计划或联合用药对乳腺癌早期患者无进展生存期的影响

争议与探索:陈益定教授解读乳腺癌内分泌强化治疗现状与临床指征

内分泌治疗贯穿乳腺癌患者从辅助治疗到挽救治疗的整个临床过程。近年来,伴随着相关临床试验的不断开展和新药的涌现,内分泌治疗发展迅速,但随之而来的问题与争议也层出不穷。不少临床医生都有这样的困惑,到底哪些患者应该应用内分泌强化治疗?强化治疗应该如何使用?